Grandbridge Limited, an investment company, engages in the development of companies, products, and services in the private and public equity markets in Australia, the United States, Europe, and Asia.
The company, through its investments in BPH Energy, engages in commercializing a portfolio of Australian biomedical technologies emerging from research by various universities, medical institutes, and hospitals.
Its technologies include BacTrak, a method of detecting infectious diseases; Brain Anaesthesia Response (BAR) Monitor, a device that measures a patient’s brain electrical activity to indicate the response to drugs administered during surgery; HLS5 Tumour Suppress Gene, a molecular marker for early and accurate cancer detection; and microtubule drugs, which target the tumour vasculature. The company also holds investments in MEC Resources that provides development and exploration funding to selected companies in the energy and mineral exploration sectors; and Advent Energy, an oil and gas exploration and production company in Western Australia.
In addition, Grandbridge (through its investments in E-Shares) provides non-advisory Internet share trading service to end user retail and wholesale customers through the trade execution and clearing service, as well as involved in trading ASX quoted equities and options, delivering up-to-date and historical market information, and underwriting new issues of securities, as well as offers a portfolio management tools.
It also provides corporate advisory services including assisting with corporate structuring/restructuring, development funding and IPO’s, corporate recognition, and strategic development to biotechnology, oil and gas, agriculture, technology, and mining sectors; and consulting services in the areas of strategy and corporate affairs, clients seeking market expansion, strategic partnerships, or investment funding.
In February 2020, the company was delisted from the ASX.